{"protocolSection":{"identificationModule":{"nctId":"NCT06477926","orgStudyIdInfo":{"id":"M25-176"},"organization":{"fullName":"AbbVie","class":"INDUSTRY"},"briefTitle":"A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended-Release Formulations in Adult Participants","officialTitle":"A Phase 1 Relative Bioavailability and Food Effect Study of ABBV-668 Extended-Release Formulations"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-06-28","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2024-09-22","type":"ESTIMATED"},"completionDateStruct":{"date":"2024-09-22","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-24","studyFirstSubmitQcDate":"2024-06-24","studyFirstPostDateStruct":{"date":"2024-06-27","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-24","lastUpdatePostDateStruct":{"date":"2024-06-27","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"AbbVie","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"The objectives of this study are to assess safety and tolerability of the new ABBV-668 ER tablets, to assess the oral bioavailability of the ABBV-668 ER tablets relative to the ABBV-668 IR capsules, and to assess the pharmacokinetics of the ER tablets under fasting and fed conditions in healthy adults."},"conditionsModule":{"conditions":["Healthy Volunteers"],"keywords":["Healthy Volunteers","ABBV-668"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"CROSSOVER","primaryPurpose":"BASIC_SCIENCE","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":24,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"ABBV-668 Regimen A","type":"EXPERIMENTAL","description":"Participants will receive ABBV-668 Immediate Release (IR) capsules on Day 1 under fasting conditions","interventionNames":["Drug: ABBV-668 IR"]},{"label":"ABBV-668 Regimen B","type":"EXPERIMENTAL","description":"Participants will receive ABBV-668 Extended Release (ER) tablets Formulation 1 administered on day 1 under fasting conditions","interventionNames":["Drug: ABBV-668 ER"]},{"label":"ABBV-668 Regimen C","type":"EXPERIMENTAL","description":"Participants will receive ABBV-668 Extended Release (ER) tablets Formulation 1 administered on day 1 under fed conditions","interventionNames":["Drug: ABBV-668 ER"]},{"label":"ABBV-668 Regimen D","type":"EXPERIMENTAL","description":"Participants will receive ABBV-668 Extended Release (ER) tablets Formulation 2 administered on day 1 under fasting conditions","interventionNames":["Drug: ABBV-668 ER"]},{"label":"ABBV-668 Regimen E","type":"EXPERIMENTAL","description":"Participants will receive ABBV-668 Extended Release (ER) tablets Formulation 2 administered on day 1 under fed conditions","interventionNames":["Drug: ABBV-668 ER"]},{"label":"ABBV-668 Regimen F","type":"EXPERIMENTAL","description":"Participants will receive ABBV-668 Extended Release (ER) tablets Formulation 3 administered on day 1 under fasting conditions","interventionNames":["Drug: ABBV-668 ER"]},{"label":"ABBV-668 Regimen G","type":"EXPERIMENTAL","description":"Participants will receive ABBV-668 Extended Release (ER) tablets Formulation 3 administered on day 1 under fed conditions","interventionNames":["Drug: ABBV-668 ER"]}],"interventions":[{"type":"DRUG","name":"ABBV-668 IR","description":"• Oral Capsule","armGroupLabels":["ABBV-668 Regimen A"]},{"type":"DRUG","name":"ABBV-668 ER","description":"• Oral Tablets","armGroupLabels":["ABBV-668 Regimen B","ABBV-668 Regimen C","ABBV-668 Regimen D","ABBV-668 Regimen E","ABBV-668 Regimen F","ABBV-668 Regimen G"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Maximum Plasma Concentration (Cmax) of ABBV-668","description":"Cmax of ABBV-668","timeFrame":"Up to approximately 47 days"},{"measure":"Time to Cmax (Tmax) of ABBV-668","description":"Tmax of ABBV-668","timeFrame":"Up to approximately 47 days"},{"measure":"Terminal Phase Elimination Rate Constant (Beta) of ABBV-668","description":"Terminal phase elimination rate constant (beta) of ABBV-668","timeFrame":"Up to approximately 47 days"},{"measure":"Terminal Phase Elimination Half-Life (t1/2) of ABBV-668","description":"Terminal phase elimination half-life of ABBV-668","timeFrame":"Up to approximately 47 days"},{"measure":"Area Under the Concentration-Time Curve From Time 0 to Time t (AUCt) of ABBV-668","description":"AUCt of ABBV-668","timeFrame":"Up to approximately 47 days"},{"measure":"Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of ABBV-688","description":"AUCinf of ABBV-688","timeFrame":"Up to approximately 47 days"},{"measure":"Number of Participants With Adverse Events (AEs)","description":"An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study","timeFrame":"Up to Day 47"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* BMI is ≥ 18.0 to ≤ 32.0 kg/m\\^2 after rounding to the tenths decimal at screening.\n* A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG.\n\nExclusion Criteria:\n\n* History of any clinically significant sensitivity or allergy to any medication or food.\n* History of any investigational drug within 30 days or 5 half-lives of the drug (whichever is longer) prior to the first dose of study drug or is currently enrolled in another clinical study or was previously enrolled in this study.\n* History of epilepsy, any clinically significant cardiac, respiratory (except mild asthma as a child), renal, hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, or any uncontrolled medical illness.\n* Participant using any medication, vitamins and/or herbal supplements (including traditional Chinese medicine), with the exception of hormonal replacement therapies for females, on a regular basis.\n* Any use of tobacco or nicotine-containing products within 180 days prior to the first dose of study drug.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"60 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"ABBVIE CALL CENTER","role":"CONTACT","phone":"844-663-3742","email":"abbvieclinicaltrials@abbvie.com"}],"overallOfficials":[{"name":"ABBVIE INC.","affiliation":"AbbVie","role":"STUDY_DIRECTOR"}]},"referencesModule":{"seeAlsoLinks":[{"label":"Related Info","url":"https://www.abbvieclinicaltrials.com/study/?id=M25-176"}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"}},"hasResults":false}